Non-alcoholic fatty liver disease and COVID-19: Harmless companions or disease intensifier?  

作　　者：Christoph G Dietrich Andreas Geier Uta Merle 

机构地区：[1]Gastro-Praxis Wiesbaden,Leberzentrum Wiesbaden,Wiesbaden 65189,Germany [2]Division of Hepatology,Department of Medicine II,University Hospital Wuerzburg,Wuerzburg 97080,Germany [3]Department of Gastroenterology and Hepatology,University Hospital Heidelberg,Heidelberg 69120,Germany

出　　处：《World Journal of Gastroenterology》2023年第2期367-377,共11页世界胃肠病学杂志（英文版）

摘　　要：The pandemics of coronavirus disease 2019(COVID-19)and non-alcoholic fatty liver disease(NAFLD)coexist.Elevated liver function tests are frequent in COVID-19 and may influence liver damage in NAFLD,while preexisting liver damage from NAFLD may influence the course of COVID-19.However,the prognostic relevance of this interaction,though,is unclear.Obesity is a risk factor for the presence of NAFLD as well as a severe course of COVID-19.Cohort studies reveal conflicting results regarding the influence of NAFLD presence on COVID-19 illness severity.Striking molecular similarities of cytokine pathways in both diseases,including postacute sequelae of COVID-19,suggest common pathways for chronic low-activity inflammation.This review will summarize existing data regarding the interaction of both diseases and discuss possible mechanisms of the influence of one disease on the other.

关 键 词：COVID-19 Postacute sequelae of COVID-19 Non-alcoholic fatty liver disease Non-alcoholic steatohepatitis INFLAMMATION Fatty liver 

分 类 号：R575.5[医药卫生—消化系统]